Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 4/20 | 0.33 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925244 | 0.94 | FAAH (0.41) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL25259222 | 0.94 | FAAH (0.41) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL3305780 | 0.83 | FAAH (0.44) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL11830328 | 0.82 | KDM4E (0.45) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL31558663 | 0.81 | FAAH (0.40) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL21859013 | 0.81 | FAAH (0.40) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL21859005 | 0.81 | FAAH (0.40) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL3961838 | 0.81 | KDM4E (0.44) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL21859010 | 0.80 | FAAH (0.39) | KDM4ENPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL23672278 | 0.80 | FAAH (0.39) | KDM4ENPC1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997871-B | Liquid crystal compound | 默克专利股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-110997871-A | Liquid crystal compounds | 默克专利股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034588-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2019-02-21 | — | — | WO | disclosed |
| US-20180142061-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | UNIV VANDERBILT (US) | 2018-05-24 | — | — | US | disclosed |
| US-9856348-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160237208-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | UNIV VANDERBILT (US) | 2016-08-18 | — | — | US | disclosed |
| US-8492510-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | VANDERBILT UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-8067136-B2 | Charge control agent, toner, image forming method, and image forming apparatus | CANON KABUSHIKI KAISHA (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110274620-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | NATIONAL SCIENCE FOUNDATION | 2011-11-10 | — | — | US | disclosed |
| US-20050287484-A1 | Resin-coated carrier for electrophotographic developer | CANON KABUSHIKI KAISHA (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005121904-A1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121204-A2 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-6774126-B2 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6552052-B2 | (2S,3Z)-2-amino-5-(6,7,8,9-tetrahydro-3-oxo-3H,5H -(1,2,4)oxadiazolo(4,3-a)azepin-5-yl)-3-pentenoic acid, for example | MONSANTO/G.D. SEARLE | 2003-04-22 | — | — | US | disclosed |
| US-6489323-B1 | INHIBITING NO PRODUCTION FROM L-ARGININE, AS SEEN IN DISEASE STATES SUCH AS ARTHRITIS AND SYSTEMIC HYPOTENSION ASSOCIATED WITH SEPTIC AND/OR TOXIC SHOCK | G.D. SEARLE & CO. | 2002-12-03 | — | — | US | disclosed |
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | HANSEN DONALD W (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1086108-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. Searle & Co. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064426-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | KDM4E 3181/4885NPC1 1760/4885RAB9A 3913/4885 |
| US-20110274620-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | DSTN, PARN, CTSA | KDM4E 2491/4885NPC1 828/4885RAB9A 1780/4885 |
| US-20180142061-A1 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities | DSTN, PARN, CTSA | KDM4E 2491/4885NPC1 828/4885RAB9A 1780/4885 |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | DSTN, PARN, CTSA | KDM4E 2491/4885NPC1 828/4885RAB9A 1780/4885 |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | KDM4E 1973/4885NPC1 2976/4885RAB9A 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.